{"id":106497,"date":"2021-02-08T12:11:04","date_gmt":"2021-02-08T12:11:04","guid":{"rendered":"https:\/\/fin2me.com\/?p=106497"},"modified":"2021-02-08T12:11:04","modified_gmt":"2021-02-08T12:11:04","slug":"czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/","title":{"rendered":"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies"},"content":{"rendered":"
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS\/Brendan McDermid\/File Photo<\/figcaption>

PRAGUE (Reuters) – The Czech Health Ministry will recommend the use of COVID-19 therapies that contain casirivimab\/imdevimab and bamlavinimab antibodies ahead of standard approval, the ministry said on Monday.<\/p>\n

Both therapies are being reviewed by the European Medicines Agency (EMA), the agency said last week.<\/p>\n

The Czech Republic has been among the European countries worst hit by the current wave of the coronavirus pandemic, with the number of new infections per 100,000 people higher only in Portugal and Spain, according to data from the European Centre for Disease Prevention and Control (ECDC) released last week.<\/p>\n

\u201cThe Ministry will recommend distribution and use of unregistered treatments which contain casirivimab\/imdevimab and bamlavinimab antibodies,\u201d the ministry said.<\/p>\n

It said it would wait for an expert opinion from the national drug agency SUKL before issuing a final ruling.<\/p>\n

The former points to Regeneron\u2019s cocktail of casirivimab and imdevimab, which was authorised for emergency use in the United States in November, and was given to then U.S. president Donald Trump during his COVID-19 infection.<\/p>\n

The latter, Eli Lilly\u2019s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk ofhospitalisation and death in COVID-19 patients by 70%, data froma late-stage trial showed in January.<\/p>\n

Czechs should receive the first 500 doses of the therapy in February, Prime Minister Andrej Babis said last Friday.<\/p>\n

The ministry said the treatment would be beneficial mainly for patients with high risk of deterioration, such as people who had received organ transplants.<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. […]<\/p>\n","protected":false},"author":3,"featured_media":106496,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nCzech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me\" \/>\n<meta property=\"og:description\" content=\"FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-08T12:11:04+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/02\/cnewsfotor11-1.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/\",\"url\":\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/\",\"name\":\"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2021-02-08T12:11:04+00:00\",\"dateModified\":\"2021-02-08T12:11:04+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Markets\",\"item\":\"https:\/\/fin2me.com\/category\/markets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me","og_description":"FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. [...]","og_url":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/","og_site_name":"Fin2me","article_published_time":"2021-02-08T12:11:04+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/02\/cnewsfotor11-1.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/","url":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/","name":"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2021-02-08T12:11:04+00:00","dateModified":"2021-02-08T12:11:04+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/markets\/czech-health-ministry-recommends-use-of-lilly-and-regeneron-covid-19-antibody-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Markets","item":"https:\/\/fin2me.com\/category\/markets\/"},{"@type":"ListItem","position":3,"name":"Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/106497"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=106497"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/106497\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/106496"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=106497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=106497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=106497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}